ALK and metastatic neoplasm: Recently, the third-generation ALK inhibitor lorlatinib has been received an accelerated approval by the U.S. FDA for patients with ALK-positive NSCLC whose metastatic disease were ineffective in response to targeted therapies such as crizotinib, ceritinib, alectinib, and brigatinib (Johnson et al., 2014).